Sun Pharma and and Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing essential dermatological conditions today announced the signing of License and Supply Agreements for Winlevi (clascoterone cream 1%) in the United States and Canada. Winlevi has been approved by the United States Food and Drug Administration FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older.
- Read more about Sun Pharma and Cassiopea SpA Signing of License and Supply Agreements for Winlevi in US and Canada
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/sun-pharma-and-cassiopea-spa-signing-of-license-and-supply-agreements-for-winlevi-in-us-and-canada
No comments:
Post a Comment